Perrigo Company (PRGO) Q2 Earnings: What's In The Cards?
Zacks Investment Research | Aug 07, 2017 11:27PM ET
Perrigo Company plc (NYSE:PRGO) is expected to report second-quarter 2017 results before the opening bell on Aug 10. Overall, the company has an average trailing four-quarter positive earnings surprise of 2.47%. Last quarter, the company delivered a positive surprise of 7.14%.
Perrigo Company Price and EPS Surprise
industry witnessed an increase of 18.3%.
Let’s see how things are shaping up at the company this quarter.
Factors Influencing This Quarter
Price erosion and changing market dynamics across Perrigo’s Prescription Pharmaceuticals (Rx) segment is likely to continue hurting the company’s performance. The company continues to expect a tough drug pricing environment to impact the segment’s performance. It anticipates price erosion of approximately 9-10% at the Rx segment in the coming quarters.
The Branded Consumer Healthcare (BCH) business, a part of Consumer Health Care International (CHCI) segment, is still being impacted by unfavorable market dynamics in countries like Belgium, France, Germany and Italy. This BCH segment is projected to underperform in the yet-to-be-reported quarter due to lower-than-expected revenues from certain high-margin products.
The U.S. Department of Justice Antitrust Division has been conducting an investigation at Perrigo, seeking information about the latter’s drug pricing practices. In May, the company announced that search warrants were executed at its corporate offices associated with the ongoing investigation. Hence, the company’s pricing strategies might get affected by such probes.
However, Perrigo’s constant focus to pursue additional branded OTC opportunities in the U.S. market as well as product acquisitions and new products launches in the Rx segment are expected to boost sales in the future quarters. The ongoing restructuring initiatives and operating expense discipline are expected to support the bottom line.
Earnings Whispers
Our proven model does not conclusively show that Perrigo is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here as you will see below.
Zacks ESP: The Earnings ESP for Perrigo is -2.13% as the Most Accurate estimate is pegged at 92 cents per share, while the Zacks Consensus Estimate stands at 94 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter .
Get The News You Want
Zacks Rank: Although Perrigo’s Zacks Rank #3 (Hold) increases the predictive power of ESP, its negative Earnings ESP leaves our earnings surprise prediction inconclusive.
We caution against all Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks that Warrant a Look
Here are some other companies to consider as our model shows that they have the right combination of elements to come up with an earnings beat this quarter:
Zoetis Inc. (NYSE:ZTS) is scheduled to release results on Aug 8 with an Earnings ESP of +1.89% and a Zacks Rank #3. You can see .
Tesaro, Inc. (NASDAQ:TSRO) is scheduled to release results on Aug 8. The company has an Earnings ESP of +17.06% and a Zacks Rank #3.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) is scheduled to release results on Aug 8. The company has an Earnings ESP of +17.37% and a Zacks Rank #3.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.